Potential of anti-inflammatory treatment for cystic fibrosis lung disease
Jennifer L Taylor-Cousar1,2, Kelsey A Von Kessel2, Robert Young1, David P Nichols1,21Department of Medicine, National Jewish Health, Denver, Colorado, USA; 2Department of Pediatrics, National Jewish Health, Denver, Colorado, USAAbstract: Cystic fibrosis (CF) is the most common life-shortening geneti...
Guardado en:
Autores principales: | Jennifer L Taylor-Cousar, Kelsey A Von Kessel, Robert Young, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5baa09982483470f853a717619a5227a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Bergin DA, et al.
Publicado: (2013) -
Inflammatory mechanisms in the lung
por: B Moldoveanu, et al.
Publicado: (2008) -
Anti-inflammatory effects of budesonide in human lung fibroblasts are independent of histone deacetylase 2
por: Wang X, et al.
Publicado: (2013) -
The immunomodulatory effect of inhaled granulocyte-macrophage colony-stimulating factor in cystic fibrosis. A new treatment paradigm
por: Heslet L, et al.
Publicado: (2012) -
Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis
por: Todd NW, et al.
Publicado: (2013)